Monday, January 12, 2009

From the Department of Too-Perfect Names ...

... comes this:
Warner Chilcott Limited today [1-7-2009] announced that it has signed an agreement with Dong-A PharmTech Co. Ltd., based in Korea, to develop and market their orally-administered udenafil product, a phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED) in the United States. Dong-A has successfully completed Phase 2 studies of the product in the United States.
Got that? Vi*agra is about to get a new competitor, developed by a company named Dong-A.

I can only assume it means something different in Korean.

Mind you, I'm not mocking the product at all. It's reportedly effective but may have fewer side effects than
Vi*agra. That could be a real boon to the substantial number of men who give up PDE5 inhibitors because they get spooky vision changes, severe headaches, or other untoward symptoms.

In the meantime, I bet some enterprising pharma company is working its way up toward Willie-Z.

No comments: